Relay Therapeutics
RLAY
94 hedge funds and large institutions have $3.64B invested in Relay Therapeutics in 2020 Q3 according to their latest regulatory filings, with 94 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
100.36% more ownership
Funds ownership: 0% → 100.36% (+100%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SIAU
SB Investment Advisers (UK)
London,
United Kingdom
|
+$1.06B |
| 2 |
TGI
TRV GP III
Boston,
Massachusetts
|
+$402M |
| 3 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$216M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$184M |
| 5 |
CC
Casdin Capital
New York
|
+$145M |
Top Sellers
RLAY Hedge Fund Activity: Q3 2020 in Review
94 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Relay Therapeutics (RLAY) for Q3 2020, worth a combined $3.64B.
Buyers outnumbered sellers: 94 funds opened new RLAY positions and 0 closed out — a net gain of 94 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was SB Investment Advisers (UK), opening a new position worth an estimated $1.06B.
- 94 institutional investors held Relay Therapeutics (RLAY) as of Q3 2020, up from 0 in Q2 2020.
- Funds reported $3.64B of Relay Therapeutics stock for Q3 2020.
- 94 funds opened new Relay Therapeutics positions in Q3 2020 and 0 closed out, a net change of +94 holders.
- The largest Relay Therapeutics buyer in Q3 2020 was SB Investment Advisers (UK), an estimated $1.06B added.
Based on aggregated 13F filings for Q3 2020.